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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB), resistance to at least isoniazid and rifampin, is a worldwide
problem.
Objective: To develop a clinical prediction rule to stratify risk for MDR-TB among patients with pulmonary tuberculosis.
Methods: Derivation and internal validation of the rule among adult patients prospectively recruited from 37 health centers
(Peru ´), either a) presenting with a positive acid-fast bacillus smear, or b) had failed therapy or had a relapse within the first
12 months.
Results: Among 964 patients, 82 had MDR-TB (prevalence, 8.5%). Variables included were MDR-TB contact within the family,
previous tuberculosis, cavitary radiologic pattern, and abnormal lung exam. The area under the receiver-operating curve
(AUROC) was 0.76. Selecting a cut-off score of one or greater resulted in a sensitivity of 72.6%, specificity of 62.8%, likelihood
ratio (LR) positive of 1.95, and LR negative of 0.44. Similarly, selecting a cut-off score of two or greater resulted in a
sensitivity of 60.8%, specificity of 87.5%, LR positive of 4.85, and LR negative of 0.45. Finally, selecting a cut-off score of three
or greater resulted in a sensitivity of 45.1%, specificity of 95.3%, LR positive of 9.56, and LR negative of 0.58.
Conclusion: A simple clinical prediction rule at presentation can stratify risk for MDR-TB. If further validated, the rule could
be used for management decisions in resource-limited areas.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB), defined as resis-
tance to at least isoniazid and rifampin, is a growing problem [1].
Worldwide, the number of MDR-TB cases reached an estimated
390,000–510,000 in 2008, or 3.6% of all incident TB cases [2].
The global expenditures in diagnosis and treating MDR-TB and
extremely drug-resistant tuberculosis (XDR-TB) were estimated at
U.S. $700 million for 2009 [3]. The cost of treating a person with
MDR-TB is estimated to be 50 to 200 times higher than treating a
patient with drug-susceptible TB [2], or $10,000 versus $100 for a
susceptible TB case [3].
Culture with drug susceptibility testing (DST) and molecular
markers are essential for properly managing drug susceptible
and MDR-TB. Unfortunately, such tests are lengthy, costly,
and not universally available in resource-limited settings,
which bear the major burden of MDR- and XDR-TB. WHO
estimates that up to 96% of patients with MDR-TB are not
being diagnosed and treated according to international
guidelines [4,5,6]. Therefore, it is imperative to develop new
methodologies for faster and affordable DST, as well as low-
cost techniques, for easier identification of patients at risk for
MDR-TB.
Clinical prediction rules (CPR) are simple, standardized clinical
tools that utilize components of history, physical examination and
basic testing to stratify risk, help make a diagnosis, or predict an
outcome [7,8,9]. In tuberculosis, CPR were developed to focus on
infection control decisions [10,11,12], the diagnosis of smear-
negative pulmonary TB [13], and prognosis [14]. In a recent
retrospective study, a CPR was developed to predict the presence
of drug-resistant TB in a high HIV prevalent area – Thailand
[15]. We developed a clinical prediction rule, with prospectively
collected data, to stratify risk for MDR-TB among patients with
pulmonary tuberculosis.
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Ethics Statement
The Ethics Committee of Universidad Peruana Cayetano Heredia
approved the clinical trial protocol, where all patients provided
written informed consent for their information to be stored in the
hospital database and used for research. The Ethics Committee of
Universidad Peruana Cayetano Heredia and the Institutional Review
Board of the University of Alabama at Birmingham approved the
use of the existing data for the purposes of this study (patient
consent was not obtained again).
Design and Patients
We derive the clinical prediction rule from data collected in a
prospective cohort study, from a phase 3 clinical trial to evaluate
rapid diagnostic tests for MDR-TB conducted in Lima, Peru ´ from
May 2004 to June 2005 [16]; patients were enrolled from 37
health care centers. The health centers are located in poor
shantytown areas of Lima (population 7.5 million). Patients were
enrolled in the trial if: a) there was a clinical suspicion of
pulmonary TB with an initial positive acid-fast bacillus (AFB)
smear, or b) had failed therapy or if they had a relapse within the
first 12 months; all patients underwent a sputum culture. At the
time the trial was conducted, the prevalence of MDR-TB was
5?3% in the area of Lima where it was executed [17].
The data obtained comprises demographic characteristics, risk
factors for acquiring MDR-TB, associated conditions, symptoms,
physical exam and radiographic findings. The risk factors studied
were history of prior TB (failed therapy or relapse within the first
12 months of standard therapy) [18,19,20,21,22], MDR-TB
contact [20], HIV [18,20], history of imprisonment [21,22,23],
and health care workers [20,24]. Physical exam findings were
classified as normal or abnormal; for example, for the lung exam,
the presence of crackles, decreased breath sounds, or other
abnormalities. Study physicians classified chest radiographic
findings and supplemented data collection by concurrent medical
record review. Susceptibility testing was performed by the indirect
proportion method on Lowenstein-Jensen media at the National
Institute of Health in Lima; personnel performing the culture were
unaware of these clinical or radiological characteristics.
Statistical Analysis
The analytical strategy was as follows: first, we defined the
patients to be included in the dataset to derive the CPR. Then, we
performed bivariate analyses of all of the candidate variables with
culture positive MDR-TB as the main outcome of interest. The
third step was building a logistic regression model including the
variables identified in the bivariate analyses. Finally, we conducted
analyses to determine the discrimination characteristics of the tool
and tested its validity and robustness.
Score Derivation
Patients included in the derivation cohort were at least 18 years
of age, had an initial suspicion of pulmonary TB with a positive
AFB smear, and had culture-proven pulmonary TB.
We performed bivariate analyses using the chi-square test for
nominal categories and the t-test for continuous variables to
narrow the list of potential predictor variables.
We then performed a forward logistic regression model using
candidate variables that had the two following characteristics: first
the variable had to be identified in the bivariate analyses at a p
level of ,0?20; second this variable had to be present in at least
5% of the study sample. Variables with a p level of ,0?05 were
retained in the final model. Only patients with complete data on
all covariates were included in this step.
We calculated the area under the receiver operating curve
(AUROC) after computing the predicted probability for each
patient using the logistic regression coefficients to assess the
discrimination of the model.
The final model was used to derive a simple and clinically
applicable risk score. We assigned 1 point to the smallest
regression coefficient and serving it as the least common
denominator for assigning point values for the score items; then
we rounded it up to the next integer as described by Le Gal and
colleagues [25]. To avoid negative numbers in the overall score,
we added a minimum integer to re-scale the lowest value to zero.
We then explored the predictive accuracy of the score by the
proportion of patients with pulmonary MDR-TB in each category
(prevalence or pretest probability) and calculated the 95%
confidence intervals for incremental likelihood ratios [26].
Model Validation
We performed internal validation of the modeling approach and
the final model in two ways. First, we tested the predictive ability
of the model by determining the goodness-of-fit with the Hosmer-
Lemeshow test; a p-value .0?05 suggests a non-significant
discrepancy between the observed and predictive events. Second,
we bootstrapped the full model 2,000 times and obtained bias-
corrected and accelerated (BCa) 95% confidence intervals to assess
the stability of the regression coefficients from logistic regression.
We decided to utilize bootstrapping as it requires less distributional
assumptions and utilizes a larger sample size as compared to other
methods (split sample or jackknife). The BCa method adjusts for
bias in the bootstrapped sampling distributions [27].
We performed nested logistic regression and computed
sequential partial R tests to assess the relative contribution of
adding the variables included in the final model. The first partial R
test was calculated when all identified clinical variables were
included. The second partial R test was calculated after adding the
radiological findings. The final R test was calculated after we
forced two important social risk factors (prior imprisonment and
health care workers). We chose this strategy because the
radiological variable was available only in a subset of patients
and because prior imprisonment and health care workers have
been associated with MDR-TB [21,22,23]. Finally, we compared
AUROCs for these three models.
We used STATA 10?1 software for all statistical analyses
(StataCorp, College Station, TX, USA).
Results
Among 964 patients with proven pulmonary TB, 82 had MDR-
TB (prevalence, 8.51%; 95% confidence interval, 6.75%–10.27%).
Complete data on all covariates was available for 75?6% (729/
964). Table 1 presents the demographic, clinical and radiographic
characteristics of the derivation sample.
Score Derivation
In the bivariate analysis, we found an association at p,0?20
between pulmonary MDR-TB and four risk factors, two co-
morbidities, five symptoms, seven physical exam findings, and one
radiographic pattern (Table 1).
In the logistic regression analysis, variables retained in the full
model included prior TB, MDR-TB contact within family,
abnormal lung exam, and cavitary pattern in the chest radiographs
(adjusted R2=21.%, p,0?001). The AUROC was 0.76 (95% CI
0.68 to 0.84).
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MDR-TB increased by clinical probability category, low (3.2%),
intermediate (6.0%), and high (41.8%) (p,0.001), Table 3.
Similarly, the likelihood ratios (LR) increased by clinical
probability category, (LR 0.4), intermediate (LR 0.8), and high
(LR 9.6), Table 3.
Selecting a cut-off score of one or greater, resulted in a
sensitivity of 72.6%, specificity of 62.8%, LR positive of 1.95, and
LR negative of 0.44 (correctly classified 63.5%). Similarly,
selecting a cut-off score of two or greater, resulted in a sensitivity
of 60.8%, specificity of 87.5%, LR positive of 4.85, and LR
negative of 0.45 (correctly classified 85.6%). Finally, selecting a
cut-off score of three or greater, resulted in a sensitivity of 45.1%,
specificity of 95.3%, LR positive of 9.56, and LR negative of 0.58
(correctly classified 91.8%).
A history of prior TB had a sensitivity of 40.2% and a specificity
of 95.8%; a history of MDR-TB contact within family had a
sensitivity of 18.3% and a specificity of 91.6%.
Model Validation
We did not observe a significant discrepancy between the
observed and predictive number of patients with MDR-TB
(p=0.39), indicating an adequate goodness-of-fit for the full
model. The bias-corrected and accelerated (BCa) 95% confidence
Table 1. Study Population Characteristics.
Variable* Total (N=964) MDR-TB (n=82) Non- MDR-TB (n=882) p-value
Demographics
Age, years, mean 6 SD 30?6610?52 9 ?7610?93 0 ?6610?50 ?44
Gender, male 583 (60?5%) 51 (62?2%) 532 (60?3%) 0?74
Risk factors
History of tuberculosis{ 70 (7?3%) 33 (40?2%) 37 (4?2%) ,0?001
MDR-TB contact, family 89 (9?2%) 15 (18?3%) 74 (8?4%) 0?003
MDR-TB contact, other 117 (12?1%) 16 (19?5%) 101 (11?5%) 0?03
TB, family death 78 (8?1%) 12 (14?8%) 66 (7?5%) 0?02
TB contact 529 (54?9%) 48 (58?5%) 481 (54?5%) 0?49
History of imprisonment 58 (6%) 3 (3?7%) 55 (6?3%) 0?35
Health care worker 42 (4?4%) 4 (4?9%) 38 (4?3%) 0?81
Co-morbidities
Alcohol use 146 (15?2%) 4 (4?9%) 142 (16?1%) 0?007
Smoker 123 (12?8%) 2 (2?4%) 121 (13?7%) 0?003
Drug use 84 (8?7%) 7 (8?5%) 77 (8?7%) 0?95
Diabetes mellitus 20 (2?1%) 2 (2?4%) 18 (2%) 0?81
HIV/AIDS 3 (0?3%) 0 (0%) 3 (0?3%) 0?60
Symptoms
Decreased appetite 497 (51?8%) 36 (44?4%) 461 (52?5%) 0?17
Weight loss 714 (74?4%) 51 (63?0%) 663 (75?4%) 0?01
Fever, sweat, or chills 773 (80?2%) 58 (70?7%) 715 (81?1%) 0?03
Cough, productive 890 (92?7%) 71 (87?7%) 819 (93?2%) 0?07
Hemoptysis 418 (43?5%) 37 (45?7%) 381 (43?3%) 0?67
Dyspnea 685 (71?4%) 52 (64?2%) 633 (72%) 0?14
Physical Exam Findings
Weight, Kg, mean (SD) 55?3695 6 ?569?75 5 ?2690 ?19
Systolic blood pressure, mmHg, mean (SD) 101?3613?61 0 4 ?4614?3 101613?50 ?03
Lung, abnormal 773 (80?6%) 60 (74?1%) 713 (81?2%) 0?12
Cardiac, abnormal 118 (12?3%) 4 (4?9%) 114 (13%) 0?04
Abdominal, abnormal 23 (2?4%) 0 (0%) 23 (2?6%) 0?14
Skin, abnormal 483 (50?3%) 34 (42?0%) 449 (51?1%) 0?12
Chest radiograph pattern
Cavitary 98 (13?4%) 13 (25?5%) 85 (12?5%) 0?009
Alveolar 116 (15?9%) 5 (10?0%) 111 (16?3%) 0?24
Reticular 90 (12?3%) 8 (15?7%) 82 (12?1%) 0?45
Nodular 13 (1?8%) 0 (0%) 13 (1?9%) 0?32
*Data is expressed as n (%) or mean 6 SD.
{Failed therapy or early relapse within 12 months.
doi:10.1371/journal.pone.0012082.t001
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bounds were similar as compared to the 95% confidence intervals
from the logistic regression model (data not shown).
The nested logistic regression illustrated the added explanatory
power of the covariate blocks. The adjusted R2 for the model with
clinical variables (prior TB, MDR-TB contact in family, abnormal
lung exam) was 18.8% (p,0?001); the explanatory power
increased by the addition of the radiologic cavitary pattern
(adjusted R2=20.2%, p=0.02); and finally, the explanatory
power did not increase by forcing the two social risk factors,
history of imprisonment and health care worker (adjusted
R2=21.3%, p=0.15). Among patients with complete data
(n=729), the AUROC for the models with the clinical variables
alone (0.75, 95% CI 0.67 to 0.83), the clinical and radiologic
pattern (0.76, 95% CI 0.68 to 0.84) and the full model (0.77, 95%
CI 0.69 to 0.85) were not statistically different (p=0.6). Among
patients with complete data on the clinical variables (n=964), the
AUROC was 0.72 (95% CI 0.65 to 0.78).
Discussion
Our findings suggest that a simple CPR can stratify the risk for
MDR-TB among patients with pulmonary TB in an endemic
area. The rule includes and combines four readily available
variables: MDR-TB contact within family, history of prior TB,
having an abnormal lung exam, and cavitary patterns on the chest
radiographs. The strongest clinical predictors were previous
history of TB (failed or relapsed after the standard regimen) and
MDR-TB contact within family.
Our findings are consistent with other studies describing
independent risk factors for MDR-TB. Risk factors that have
been associated with MDR-TB include: prior TB [18,19,
20,21,22], known TB contacts [20], age younger than 45 years
[18,21], HIV positivity [18,20], health-care workers [20,24], and
previous imprisonment [21,22,23]. We did not find association
with age as our population was predominantly young. Similar to
other countries in Latin America, the prevalence of HIV co-
infection was low, thus assessing the association with MDR-TB
was not possible [28]. Even though we did not find statistical
association with health care workers and history of imprisonment;
we forced them into the model, because these variables have been
associated with resistant TB [18,19,20,21,22,23,24]. However,
they did not contribute to improve the goodness of fit in the final
model. These results might be explained by the low number of
patients with these risk factors into the sample. We found that
MDR-TB patients are more likely to have cavitary lesions in
accordance with previous studies [29,30]; perhaps because such
patients often have had active TB for longer periods of time and
the greater prevalence of cavitation may just reflect the prolonged
time with active TB. We can only speculate for the seemingly
protective effect of an abnormal lung exam finding for MDR-TB
risk. A protective effect for MDR-TB indicates a higher risk for
sensitive TB; since patients with cavitary lesions are more likely to
have MDR-TB, patients with sensitive TB may have an interstitial
radiographic pattern that can elicit crackles in the lung exam (this
hypothesis warrants further confirmation).
Other CPR models have been developed to assist the decision
for respiratory isolation of patients with suspected TB [10,11,12],
or in the diagnosis of smear-negative pulmonary TB [13], as well
as to predict the clinical course among patients with known TB
[14]. Clinical features identified in these studies were weight loss,
fever or night sweats, hemoptysis, age .45 years old, productive
cough, and upper-lobe infiltrate on chest radiograph or cavities.
We are not aware of any other CPR developed specifically to
stratify the risk of MDR-TB among patients with TB in endemic
or non-endemic areas. We should note a previous study performed
in Thailand [15]. Boonsarngsuk and colleagues found that chest
radiograph features, relapse after previous treatment, and prior
incomplete treatment were associated with an increased risk for
either isoniazid or rifampin resistance; a cut-off score of greater
than two had a sensitivity of 58% and a specificity of 68% [15].
However, the study was retrospective, had a small sample size (290
patients), patients were selected base on physicians’ judgment,
patients were treated in a referral hospital, and included
microbiological results from invasive procedures (bronchoalveolar
lavage fluid); the prevalence of MDR-TB was 2.4% (7 cases) and
HIV was 16%. In our study, selecting a cut-off score of two or
Table 2. Multidrug-Resistance Pulmonary Tuberculosis
(MDR-TB) Score.
Variable
Regression Coefficients
(95% BCa CI) Points
Risk factors
History of tuberculosis* 2?78 (1?98 to 3?49) 3
MDR-TB contact, family 1?27 (0?34 to 2?15) 2
Physical exam
Abnormal lung exam 20?82 (21?57 to 20?12) 21
Chest radiograph pattern
Cavitary 0?93 (0?14 to 1?66) 1
BCa = Bias-Corrected and accelerated, CI: confidence interval.
*Failed therapy or early relapse within 12 months.
doi:10.1371/journal.pone.0012082.t002
Table 3. Proportion of Patients Classified by the MDR-TB Score and Likelihood Ratios.
Clinical Probability Category Patients n (%)
MDR-TB Prevalence (Pretest
Probability) n (%) Likelihood Ratio (95% CI)
Low
(0 points)
440 (60?4) 14 (3?2) 0?4( 0 ?3t o0 ?6)
Intermediate
(1–2 points)
234 (32?1) 14 (6) 0?8( 0 ?5t o1 ?3)
High
(.2 points)
55 (7?5) 23 (41?8) 9?6( 6t o1 4 ?8)
All 729 (100) 51 (7)
MDR-TB: Multidrug-resistant tuberculosis, CI: confidence interval.
doi:10.1371/journal.pone.0012082.t003
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We built a new CPR by validating previously identified risk factors
for MDR-TB [18,19,20,21,22,23,24] as well as clinical and
radiographic findings in MDR-TB patients [29,30] for inclusion
in the model; adjusting them for multiple independent factors
single score. Furthermore, we identified the relative weighs of
independent factors and combined them in a single score. If
further validated, such a rule could be used for testing and
treatment decisions.
The present study has several strengths: first, the sample size
was large and representative of a highly prevalent area for MDR-
TB, where patients were enrolled from 37 health care centers.
Second, the data was collected prospectively in an operational
setting. Third, the culture and DST were done in a reference
laboratory that follows the standard WHO guidelines [4],
furthermore the personnel performing the DST was unaware of
the patients’ clinical or radiographic findings. Finally, we followed
recommended methodology to develop a CPR, adjusted for
independent factors and performed internal validation. Thus, our
study fulfills validity criteria for the development of a CPR.
Our study has some limitations. First, while all patients had
chest radiographs, not all films were available for interpretations as
it was not requirement for the original clinical trial. However, we
do not expect selection bias because the AUROC excluding chest
radiographs was 0.72 (n=964) and 0.74 among patients with
complete data (n=729). Second, our findings may not apply to
areas with higher prevalence of HIV/TB co-infection; in our
setting, all patients with TB are tested for HIV. Finally, similar to
other real-world operational settings, we only included patients
with positive AFB smear. As compared to culture media, the
sensitivity of AFB smear is ,80%; however, routine culture in all
patients is neither universally accepted nor a feasible practice in
developing countries.
In summary, diagnosing MDR-TB requires the use of
techniques that are of limited availability and high expense for
developing countries, such as culture in liquid media with DST, or
line probe assays [31,32,33,34,35,36]. Developing improved and
affordable diagnostic tools for MDR-TB represent priority areas in
public health research. We have developed a CPR based on easily
obtainable clinical findings (prior TB, MDR-TB contact, abnor-
mal lung exam) and one radiological pattern (cavity) in patients
with pulmonary TB to stratify the risk of MDR-TB in resource-
limited and endemic area such as Peru ´. If further validated, such a
tool may help TB programs examine the costs and benefits
implications of sensitivity testing, especially in resource-limited
endemic areas. For example, in our sample, in the 60.4% of
patients who were deemed at low risk according to the rule, the
prevalence of MDR-TB was 3.2%. In the Peruvian Tuberculosis
Program such patients do not receive culture and sensitivity testing
initially, this 3.2% of patients may continue transmission of MDR-
TB. Exploring the costs and benefits implications of testing all
patients at low risk is warranted. We are not advocating the
immediate use and implementation of such a clinical-prediction
rule. Finally, cost-effectiveness studies are needed to evaluate the
potential impact of this tool in decisions regarding treatment
regimens or infection control measures.
Acknowledgments
Dr. Estrada had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data
analysis. The opinions expressed in this article are those of the authors
alone and do not reflect the views of the Department of Veterans Affairs.
Data sharing: no additional data available.
Previous Presentation: Presented in part at the Southern American
Federation for Medical Research meeting, New Orleans, LA, February
25–27, 2010.
Author Contributions
Conceived and designed the experiments: DM GH CS GH RMC CH EG
CE. Performed the experiments: DM GH GH CZ RMC EG CE.
Analyzed the data: DM GH GH MR RMC CE. Contributed reagents/
materials/analysis tools: DM GH CS GH MR CZ RMC CH EG CE.
Wrote the paper: DM GH CS GH MR CZ RMC CH EG CE.
References
1. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, et al. (2009)
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of
the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet
373: 1861–1873.
2. WHO (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010
global report on surveillance and response. World Health Organization.
3. WHO (2009) Global Tuberculosis control and patient care. A ministerial
meeting of high M/XDR-TB burden countries. Beijing, China 1–3 April
2009.
4. WHO (2008) Guidelines for the programmatic management of drug-resistant
tuberculosis. Emergency update 2008. Geneva: World Health Organization.
5. Enarson D, Rieder H, Arnadottir T, Tre ´bucq A (2000) Management of
tuberculosis: a guide for low income countries. In: IUATLD, ed. 5th ed. Paris:
International Union against Tuberculosis and Lung Disease.
6. WHO (2006) The Stop TB Strategy. Building on and enhancing DOTS to meet
the TB-related Millennium Development Goals. Geneva: World Health
Organization.
7. Laupacis A, Sekar N, Stiell IG (1997) Clinical prediction rules. A review and
suggested modifications of methodological standards. JAMA 277: 488–
494.
8. Wasson JH, Sox HC, Neff RK, Goldman L (1985) Clinical prediction rules.
Applications and methodological standards. N Engl J Med 313: 793–
799.
9. McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, et al. (2000) Users’
guides to the medical literature: XXII: how to use articles about clinical decision
rules. Evidence-Based Medicine Working Group. JAMA 284: 79–84.
10. Wisnivesky JP, Serebrisky D, Moore C, Sacks HS, Iannuzzi MC, et al. (2005)
Validity of clinical prediction rules for isolating inpatients with suspected
tuberculosis. A systematic review. J Gen Intern Med 20: 947–952.
11. Rakoczy KS, Cohen SH, Nguyen HH (2008) Derivation and validation of a
clinical prediction score for isolation of inpatients with suspected pulmonary
tuberculosis. Infect Control Hosp Epidemiol 29: 927–932.
12. Solari L, Acuna-Villaorduna C, Soto A, Agapito J, Perez F, et al. (2008) A
clinical prediction rule for pulmonary tuberculosis in emergency departments.
Int J Tuberc Lung Dis 12: 619–624.
13. Soto A, Solari L, Agapito J, Acuna-Villaorduna C, Lambert ML, et al. (2008)
Development of a clinical scoring system for the diagnosis of smear-negative
pulmonary tuberculosis. Braz J Infect Dis 12: 128–132.
14. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, et al. (2008) TBscore:
Signs and symptoms from tuberculosis patients in a low-resource setting have
predictive value and may be used to assess clinical course. Scand J Infect Dis 40:
111–120.
15. Boonsarngsuk V, Tansirichaiya K, Kiatboonsri S (2009) Thai drug-resistant
tuberculosis predictive scores. Singapore Med J 50: 378–384.
16. Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, et al. (2008)
Cost-effectiveness analysis of introduction of rapid, alternative methods to
identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect
Dis 47: 487–495.
17. WHO (2008) Anti-Tuberculosis Drug Resistance in the World, Fourth Global
Report. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug
Resistance Surveillance 2002-2007. Geneva: World Health Organization.
18. Faustini A, Hall AJ, Perucci CA (2006) Risk factors for multidrug resistant
tuberculosis in Europe: a systematic review. Thorax 61: 158–163.
19. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, et al. (2001)
Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc
Lung Dis 5: 887–893.
20. Casal M, Vaquero M, Rinder H, Tortoli E, Grosset J, et al. (2005) A case-
control study for multidrug-resistant tuberculosis: risk factors in four European
countries. Microb Drug Resist 11: 62–67.
21. Kliiman K, Altraja A (2009) Predictors of extensively drug-resistant pulmonary
tuberculosis. Ann Intern Med 150: 766–775.
22. Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, et al. (2005)
Rates of drug resistance and risk factor analysis in civilian and prison patients
with tuberculosis in Samara Region, Russia. Thorax 60: 130–135.
Tuberculosis Prediction Rule
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e1208223. Kimerling ME, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, et al.
(1999) Inadequacy of the current WHO re-treatment regimen in a central
Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 3:
451–453.
24. Jereb JA, Klevens RM, Privett TD, Smith PJ, Crawford JT, et al. (1995)
Tuberculosis in health care workers at a hospital with an outbreak of multidrug-
resistant Mycobacterium tuberculosis. Arch Intern Med 155: 854–859.
25. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, et al. (2006) Prediction
of pulmonary embolism in the emergency department: the revised Geneva score.
Ann Intern Med 144: 165–171.
26. Koopman P (1984) Confidence intervals for the ratio of two binomial
proportions. Biometrics 40: 513–517.
27. Haukoos JS, Lewis RJ (2005) Advanced statistics: bootstrapping confidence
intervals for statistics with ‘‘difficult’’ distributions. Acad Emerg Med 12:
360–365.
28. UNAIDS/WHO (2009) Epidemiological Fact Sheet on HIV and AIDS: Peru
2008 Update. Geneva, Switzerland: UNAIDS/WHO.
29. Granich RM, Oh P, Lewis B, Porco TC, Flood J (2005) Multidrug resistance
among persons with tuberculosis in California, 1994–2003. JAMA 293:
2732–2739.
30. Ben-Dov I, Mason GR (1987) Drug-resistant tuberculosis in a southern
California hospital. Trends from 1969 to 1984. Am Rev Respir Dis 135:
1307–1310.
31. Balabanova Y, Drobniewski F, Nikolayevskyy V, Kruuner A, Malomanova N,
et al. (2009) An integrated approach to rapid diagnosis of tuberculosis and
multidrug resistance using liquid culture and molecular methods in Russia. PLoS
One 4: e7129.
32. O’Riordan P, Schwab U, Logan S, Cooke G, Wilkinson RJ, et al. (2008) Rapid
molecular detection of rifampicin resistance facilitates early diagnosis and
treatment of multi-drug resistant tuberculosis: case control study. PLoS One 3:
e3173.
33. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, et al. (2010) Rapid
screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda.
BMC Infect Dis 10: 41.
34. Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, et al. (2010)
Validation of the GenoType MTBDRplus assay for diagnosis of multidrug
resistant tuberculosis in South Vietnam. BMC Infect Dis 10: 149.
35. Richter E, Rusch-Gerdes S, Hillemann D (2009) Drug-susceptibility testing in
TB: current status and future prospects. Expert Rev Respir Med 3: 497–510.
36. Minime-Lingoupou F, Pierre-Audigier C, Kassa-Kelembho E, Barilone N,
Zandanga G, et al. (2010) Rapid identification of multidrug-resistant tuberculosis
isolates in treatment failure or relapse patients in Bangui, Central African
Republic. Int J Tuberc Lung Dis 14: 782–785.
Tuberculosis Prediction Rule
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12082